Autologous Blood Therapy for Eczema: A Better Skin Score Was Not Confirmed by Patient Ratings
Why the outcome matters
A procedure described as using your own blood can sound more familiar than a new medicine. Familiarity does not tell us whether it improves eczema in a way that matters to patients. An older controlled trial found a favorable clinician-rated skin result, while patient-rated outcomes did not clearly confirm the benefit. Both findings belong in the same account.
Thirty-one randomized participants
A 2003 double-blind placebo-controlled trial randomized 31 participants after 50 responded to advertisements. Autologous blood therapy or placebo was given weekly for five weeks, followed by five weeks of follow-up. The primary outcome was SASSAD, a clinician-rated eczema severity score. Patient-rated itching, sleep, skin appearance and dermatology quality of life were secondary outcomes.
A positive primary score, with an important qualification
Intention-to-treat analysis found an additional SASSAD reduction of 9.6 points over placebo at treatment end (95% CI 4.2–14.9), and 13.5 points at follow-up (95% CI 6.6–20.4). No clear significant between-group differences appeared on the secondary outcomes. Six active-treatment and seven placebo participants reported minor, transient adverse events. The investigators called for larger confirmatory trials.
Do not turn score points into response rates
Those differences are points on a severity scale, not percentages of participants cured or probabilities that an individual will respond. They also do not establish that every procedure advertised as autologous blood therapy is the same intervention. Platelet preparations, modified blood products and other injection services should not inherit the trial result simply because they involve a person's blood.
Why clinician and patient measures can diverge
A visible lesion assessment and a person's experience answer related but different questions. For someone balancing work, sport and family life, sleep, itching and everyday functioning can be as important as the appearance of the rash. A favorable skin score should not erase a null patient-reported result. Equally, the secondary results do not mean the reported primary analysis should be concealed. The conclusion needs to retain that disagreement.
What would make the evidence more persuasive?
A larger trial could estimate the effect more precisely, assess whether patient-important benefits are reproducible and provide better safety follow-up. A small short trial cannot establish rare harms or the consequences of repeated treatment over years. Using one's own biological material does not remove the need for evidence about a procedure, its setting and the people performing it.
Questions before committing time or money
Ask exactly which preparation is proposed, what controlled evidence supports it, which outcome is expected to improve and when progress will be reviewed. Ask how it fits with the existing eczema plan. Do not use a research summary as instructions to collect or inject blood, and do not interrupt effective treatment to pursue an unconfirmed procedure.
Keep the care plan connected to the evidence
The AAD guideline page describes evidence-based eczema treatment options and individualized management. Our study-reading guide helps interpret score changes. The itch-versus-rash score article explains why outcomes differ, while the bioresonance sham trial illustrates a different procedure that did not show an added benefit. These interventions should not be merged into one evidence claim.
For a different comparison of study outcomes, read IVIg for Childhood Eczema: Temporary Improvement, Dropouts and the Limits of a Small Trial. Compare the actual population, endpoint and follow-up rather than transferring one intervention's result to another.
Prepared by the Dr. Arsy editorial team. Sources checked November 9, 2026. Educational information does not diagnose or prescribe. AI-created sports product image; not a patient photograph or clinical result.